Newborn Screening Market Global Scale Share Expansion Forecast 2032

 

The global newborn screening market, valued at USD 520 million in 2022, is projected to reach USD 1.1 billion by 2032, growing at a CAGR of 7.8%. This growth is driven by rising infant disorder prevalence, with 3% of U.S. babies affected by birth defects, per the CDC, and high birth rates in emerging markets like India, which records 25 billion births annually, per UNICEF. The market’s significance lies in early detection of treatable conditions, reducing infant mortality and morbidity.

Consumables, particularly assay kits, dominate with an 8% CAGR, while dry blood spot tests lead test types at a 9% CAGR due to their ease of use. The U.S. market, valued at USD 310 million in 2021, grows at a 5% CAGR, while China reaches USD 850 million by 2032. The COVID-19 pandemic heightened demand as parents prioritized infant health. Challenges include high automation costs and policy gaps. The market is set for robust growth through 2032, supported by healthcare infrastructure investments and technological advancements.

For more insights into the Market, Request a Sample of this Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=6323

Market Analysis

The newborn screening market is propelled by increasing infant disorder prevalence, with congenital hearing loss affecting 30 per 100,000 children in India, per the Indian Academy of Paediatrics, and global birth rates driving demand. The COVID-19 pandemic amplified screening needs, as parents feared asymptomatic virus transmission to newborns, boosting market growth. Emerging markets like India and China, with China’s screening uptake for hypothyroidism surpassing 90% in 2021, offer significant opportunities. High automation costs and lack of standardized policies pose challenges, particularly in developing regions. Innovations like PerkinElmer’s 2020 CE-IVD-approved EONISTM assay for SMA and SCID enhance screening capabilities. North America, led by the U.S. at a 5% CAGR, and Asia-Pacific, with India at 7.7% CAGR, drive growth, supported by government initiatives to reduce infant mortality.

Segment Analysis

The market is segmented by product, test type, technology, end user, and region. Consumables, including assay kits and reagents, lead with an 8% CAGR, driven by hygiene concerns post-COVID-19. Dry blood spot tests dominate test types, growing at a 9% CAGR, due to their convenience in sample collection and transport. Immunoassays and enzymatic assays, with a 7% CAGR, are preferred for conditions like cystic fibrosis. Hospitals are the primary end users, followed by clinical laboratories, reflecting high screening volumes. North America, with a 2021 value of USD 310 million, grows at a 5% CAGR, while Asia-Pacific, particularly India and China, sees rapid expansion at 7.7% and 7.5% CAGRs, respectively, due to high birth rates and healthcare investments. The market’s diverse segments address varied clinical and regional needs.

Country-wise Insights

In the United States, the market grows at a 5% CAGR, reaching USD 540 million by 2032, driven by routine screening of billions of babies annually, per the CDC, and players like PerkinElmer offering advanced solutions. In the United Kingdom, growth at a 5.2% CAGR is supported by robust NHS screening programs and increasing awareness of early diagnosis benefits, though specific market value data is limited. The U.S. leads in scale and technological adoption, while the UK excels in policy-driven screening, ensuring sustained growth through 2032.

Key Players

• PerkinElmer
• Demant A/S
• Natus Medical Inc.
• Bio-Rad Laboratories
• Danaher Corporation
• Medtronic Plc.
• Chromsystems Instruments & Chemicals GmbH
• Trivitron Healthcare
• Baebies
• RECIPE Chemicals + Instruments GmbH

Strategic Outlook and Industry Trends

The newborn screening market is advancing through strategic acquisitions, like Natus Medical’s 2020 purchase of Baybe GmbH for remote communication technology, and innovations such as PerkinElmer’s EONISTM assay. Government initiatives in India, targeting infant mortality reduction, and China’s high screening uptake drive growth. High automation costs and competition from refurbished products remain challenges. The market is poised for steady expansion through 2032, fueled by rising birth rates, technological advancements, and increased healthcare spending in emerging markets, reshaping global infant diagnostics.

Segmentation of Newborn Screening Market

By Product:

• Instruments
• Consumables

By Test Type:

• Dry Blood Spot Tests
• Hearing Tests
• Critical Congenital Heart Disease (CCHD) Screening Tests

By Technology:

• Immunoassays & Enzymatic Screening Tests
• Tandem Mass Spectrometry
• Molecular Assays
• Pulse Oximetry
• Other Technologies

By End User:

• Clinical Laboratories
• Hospitals

By Region:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa

Contact

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Email: sales@factmr.com